Intellia Therapeutics Inc (NTLA)
20.77
+0.75
(+3.75%)
USD |
NASDAQ |
Apr 26, 16:00
20.77
0.00 (0.00%)
After-Hours: 17:41
Intellia Therapeutics Revenue (Quarterly): -1.917M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.917M |
| September 30, 2023 | 11.99M |
| June 30, 2023 | 13.59M |
| March 31, 2023 | 12.61M |
| December 31, 2022 | 13.57M |
| September 30, 2022 | 13.27M |
| June 30, 2022 | 14.03M |
| March 31, 2022 | 11.25M |
| December 31, 2021 | 12.85M |
| September 30, 2021 | 7.204M |
| June 30, 2021 | 6.55M |
| March 31, 2021 | 6.445M |
| December 31, 2020 | 6.595M |
| September 30, 2020 | 22.22M |
| June 30, 2020 | 16.26M |
| March 31, 2020 | 12.92M |
| December 31, 2019 | 10.94M |
| September 30, 2019 | 10.62M |
| Date | Value |
|---|---|
| June 30, 2019 | 11.12M |
| March 31, 2019 | 10.43M |
| December 31, 2018 | 7.88M |
| September 30, 2018 | 7.408M |
| June 30, 2018 | 7.677M |
| March 31, 2018 | 7.469M |
| December 31, 2017 | 6.668M |
| September 30, 2017 | 7.317M |
| June 30, 2017 | 5.917M |
| March 31, 2017 | 6.215M |
| December 31, 2016 | 5.627M |
| September 30, 2016 | 4.869M |
| June 30, 2016 | 4.206M |
| March 31, 2016 | 1.777M |
| December 31, 2015 | 1.693M |
| September 30, 2015 | 1.688M |
| June 30, 2015 | 1.377M |
| March 31, 2015 | 1.286M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-1.917M
Minimum
Dec 2023
22.22M
Maximum
Sep 2020
11.16M
Average
11.99M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| Moderna Inc | 2.813B |
| Regeneron Pharmaceuticals Inc | 3.434B |
| NeuroMetrix Inc | 1.318M |
| Repligen Corp | 155.74M |
| Pacific Biosciences of California Inc | 58.36M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -132.16M |
| Total Expenses (Quarterly) | 137.98M |
| EPS Diluted (Quarterly) | -1.46 |
| Enterprise Value | 1.012B |
| Earnings Yield | -26.05% |
| Normalized Earnings Yield | -26.04 |